4.3 Article

Protein-Bound Uremic Toxins from Gut Microbiota and Inflammatory Markers in Chronic Kidney Disease

期刊

JOURNAL OF RENAL NUTRITION
卷 26, 期 6, 页码 396-400

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.jrn.2016.07.005

关键词

-

资金

  1. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
  2. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
  3. Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) [E-26/102.290/2013]

向作者/读者索取更多资源

Objective: Protein-bound uremic toxins from gut microbiota tend to accumulate in chronic kidney disease (CKD) patients and are poorly removed by current dialysis techniques. These toxins induce inflammation and are associated with cardiovascular disease (CVD). The aim of this study was to report the relationship between uremic toxins and inflammatory and cardiovascular markers in CKD patients. Design: This was a cross sectional study. Subjects: Twenty-one nondialysis patients were included (43% men, 63.0 +/- 7.8 years, glomerular filtration rate: 34.4 +/- 12.5 mL/min) as well as 29 hemodialysis (HD) patients [58% men, 52.7 +/- 10.3 years, time on dialysis 54 (31-94.5 months)]. Main Outcome Measure: Total levels of uremic toxins (IS, p-CS, and IAA) were assessed by high-performance liquid chromatography with fluorescence detection. C-reactive protein, Interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and calprotectin plasma levels were determined by immunometric assays. Results: HD patients presented higher inflammatory markers and uremic toxins levels than nondialysis patients. IL-6 levels were positively correlated with IS (r = 0.49; P = .03), p-CS (r = 0.35; P = .04) and IAA (r = 0.36; P = .03). A positive correlation was also observed between MCP-1 levels with IS (r-0.72; P-.001), p-CS (r-0.48; P-.001) and IAA (r-0.75; P-.0001). Linear regression showed that IS was an independent predictor for IL-6 and MCP-1 levels after adjustment. Conclusion: Plasma uremic toxins were associated with higher IL-6 and MCP-1 levels in CKD patients, potentially playing a role in the development of CVD. (C) 2016 by the National Kidney Foundation, Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据